Team
Immune responses to cancer
Thematic areas of research:
Image
To top
Team
SEBASTIAN AMIGORENA
Immune responses to cancer
Adaptive immune responses are initiated by the clonal selection of naive T lymphocytes, which recognize their cognate ligands through antigen-specific T cell receptors. T cell receptors are specific for MHC/peptides complexes. These peptides are generated from internalized antigens that are degraded in endocytic compartments.
Members
Image
Key publications
All publications
-
-
Specific subfamilies of transposable elements contribute to different domains of T lymphocyte enhancersProceedings of the National Academy of Sciences
-
Critical role for TRIM28 and HP1β/γ in the epigenetic control of T cell metabolic reprograming and effector differentiationProceedings of the National Academy of Sciences
-
Human lymphoid organ cDC2 and macrophages play complementary roles in T follicular helper responsesJournal of Experimental Medicine
-
-
Critical role for Sec22b-dependent antigen cross-presentation in antitumor immunityJournal of Experimental Medicine
News
All news
-
Deux projets portés par l’Institut Curie lauréats du programme RHU
Deux projets d'envergure portés par l’Institut Curie sont lauréats du programme Recherche Hospitalo-Universitaire : CASSIOPEIA dans les cancers du sein triple négatifs et EpCART pour les cancers de mauvais pronostic.09/12/2021 -
Immune system: spotlight on monocyte fate
When it detects pathogens such as viruses or bacteria, our immune system triggers certain specific signaling pathways. Institut Curie’s Immune Responses to Cancer team has just identified the signals that determine monocyte differentiation into macrophages or dendritic cells.18/11/2021 -
L’Institut Curie salue la levée de fonds de 75 millions d’euros réalisée par sa spin-off Mnemo Therapeutics
L’Institut Curie salue la levée de fonds de 75 millions d’euros réalisée par sa spin-off Mnemo Therapeutics co-fondée avec le Memorial Sloan Kettering Cancer Center. Obtenue auprès d’investisseurs européens et américains, il s’agit de la plus grosse levée de fonds jamais effectuée en France par une société de biotechnologies seulement 2 ans après sa création. Fruit de longues années de recherches menées à l’Institut Curie, ces innovations augurent des perspectives prometteuses dans la lutte contre le cancer.14/06/2021
Job offers
All job offers
-
Technician or Engineer with experience in flow cytometry (M/F)
The Curie Institute Research Center
The “Institut Curie” is a major player in the research and fight against cancer. It consists of a hospital and a Research Center of more than 1000 employees with a strong international representativeness.
The objective of the Curie Institute Research Center is to develop basic research and to use the knowledge produced to improve the diagnosis, prognosis, and therapeutics of cancers as part of the continuum between basic research and innovation serving the patient.
-
Postdoctoral Position in Computational Onco-Immunology (M/F)The Curie Institute Research Center
The Institut Curie (http://www.institut-curie.org) is one of the biggest European institutions for cancer research with a strong interdisciplinary tradition. Institut Curie is located in the center of Paris in a rich scientific environment. It consists of a hospital and a Research Center of more than 1000 employees with a strong international representativeness.
The objective of the Curie Institute Research Center is to develop basic research and to use the knowledge produced to improve the diagnosis, prognosis, and therapeutics of cancers as part of the continuum between basic research and innovation serving the patient.
Partners
